---
title: "Human Growth Hormone (Somatropin)"
canonical_url: https://peptidelibrary.app/library/somatropin
description: "FDA-approved recombinant 191-aa human growth hormone for GH deficiency and other labeled indications. WADA prohibits GH at all times (S2)."
updated: 2026-10-05
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Human Growth Hormone (Somatropin)

Human Growth Hormone (Somatropin), also called Recombinant human GH or rhGH, is an FDA-approved recombinant growth hormone. Somatropin is recombinant human growth hormone with the natural 191-amino-acid sequence. It binds a preformed growth hormone receptor dimer on target cells, and the conformational change on binding activates receptor-associated JAK2, which phosphorylates STAT5 for transcriptional signalling.

FDA-approved recombinant 191-aa human growth hormone for GH deficiency and other labeled indications. WADA prohibits GH at all times (S2).

Also known as: Recombinant human GH, rhGH, Genotropin, Humatrope, Norditropin.

Categories: Fat Loss, Muscle/Recovery, GLP-1/Metabolic.

## Classification

- Type: FDA-approved recombinant growth hormone
- Mechanism class: Growth Hormone Receptor Agonist
- Development stage: Approved product
- Regulatory class: FDA-approved medicine

## Mechanism

Somatropin is recombinant human growth hormone with the natural 191-amino-acid sequence. It binds a preformed growth hormone receptor dimer on target cells, and the conformational change on binding activates receptor-associated JAK2, which phosphorylates STAT5 for transcriptional signalling. Effects fall into two groups. Indirect anabolic effects are mediated by hepatic IGF-1, induced by GH and responsible for linear growth at the epiphyseal plates. Direct effects are largely metabolic and include stimulation of lipolysis in adipose tissue and induction of hepatic and peripheral insulin resistance, which is why glucose tolerance can worsen during treatment.

Targets: Growth hormone receptor.

Origin: Recombinant human somatropin.

## Properties

- Sequence: 191 amino acids (recombinant human growth hormone)
- Molecular formula: C990H1529N263O299S7
- Molecular weight: 22,124 g/mol
- CAS number: 12629-01-5
- Half-life: 3.0–3.8 hours after subcutaneous injection in the Genotropin and Humatrope labels (7–10 hours in the Norditropin label), because absorption from the injection site is slow; 0.4 hours intravenously (Genotropin label)
- Studied routes: Subcutaneous

## Evidence

- Evidence level: FDA Approved
- Highest documented: Regulatory review (FDA label)
- Human trials: 2
- Controlled human trials: 2
- Preclinical sources: 0
- Latest source: 2010

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. GENOTROPIN (somatropin) for injection — FDA prescribing information, DailyMed. Regulatory label (FDA), human. Population: Adults with adult-onset or childhood-onset growth hormone deficiency. Replacement of endogenous growth hormone [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffebf88b-d257-4542-9808-74d9b7167765)
2. HUMATROPE (somatropin) for injection — FDA prescribing information, DailyMed. Regulatory label (FDA), human. Population: Children with growth failure due to inadequate secretion of endogenous growth hormone. Linear growth [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a774e1ae-3997-49ee-8b0e-99a2b315d409)
3. SEROSTIM (somatropin) for injection — FDA prescribing information, DailyMed. Regulatory label (FDA), human. Population: Adults with HIV and wasting or cachexia, on concomitant antiretroviral therapy. Lean body mass, body weight and physical endurance [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62b01d29-90f0-45b2-a0c4-3a750ba36c8a)
4. Blackman MR et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA. 2002. 2002. Controlled human trial. Population: Healthy community-dwelling women (n=57) and men (n=74) aged 65 to 88. Lean body mass rose and fat mass fell; strength did not increase significantly except a marginal gain with growth hormone plus testosterone in men; diabetes or glucose intolerance occurred in 18 men given growth hormone versus 7 not given it [Source](https://pubmed.ncbi.nlm.nih.gov/12425705/)
5. Meinhardt U et al. The effects of growth hormone on body composition and physical performance in recreational athletes: a randomized trial. Ann Intern Med. 2010. 2010. Controlled human trial. Population: Recreationally trained adults, 63 men and 33 women, mean age 27.9. Fat mass fell and lean body mass rose through extracellular water; sprint capacity rose by 3.9% and the gain was lost 6 weeks after stopping; endurance, strength and power did not change significantly [Source](https://pubmed.ncbi.nlm.nih.gov/20439575/)

## Safety

Side effects: Edema; Arthralgia; Carpal tunnel; Hyperglycemia; Intracranial hypertension.

Risks: WADA S2; Contraindicated in active malignancy.

Contraindications: Active malignancy; Acute critical illness; Diabetic retinopathy (proliferative/severe); Hypersensitivity to product components.

Human safety basis: FDA prescribing information

## Regulatory status

Human Growth Hormone (Somatropin) is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.

- FDA status: Approved
- WADA status: Banned in Sport
- Availability: Prescription-Only

## Frequently asked questions

### What is Human Growth Hormone (Somatropin)?

FDA-approved recombinant 191-aa human growth hormone for GH deficiency and other labeled indications. WADA prohibits GH at all times (S2).

### How does Human Growth Hormone (Somatropin) work?

Somatropin is recombinant human growth hormone with the natural 191-amino-acid sequence. It binds a preformed growth hormone receptor dimer on target cells, and the conformational change on binding activates receptor-associated JAK2, which phosphorylates STAT5 for transcriptional signalling.

### Is Human Growth Hormone (Somatropin) FDA approved?

Yes. Human Growth Hormone (Somatropin) is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.

### What is the half-life of Human Growth Hormone (Somatropin)?

Reported half-life for Human Growth Hormone (Somatropin) is ~3 hours (SC/IM absorption-limited; serum decline ~3–5 hours). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### What is the amino acid sequence of Human Growth Hormone (Somatropin)?

Human Growth Hormone (Somatropin) has the sequence 191 amino acids (recombinant human growth hormone). Its molecular formula is C990H1529N263O299S7.

### Is Human Growth Hormone (Somatropin) banned in sport?

Human Growth Hormone (Somatropin) is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

## References

- [FDA somatropin class labeling example](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020280s104lbl.pdf)
- [WADA Prohibited List 2026](https://www.wada-ama.org/en/prohibited-list)
- [Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study — J Clin Endocrinol Metab, 2022](https://pubmed.ncbi.nlm.nih.gov/35405011/)
- [Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial — J Clin Endocrinol Metab, 2021](https://pubmed.ncbi.nlm.nih.gov/34272849/)
- [Safety and Effectiveness of Recombinant Human Growth Hormone in Children with Turner Syndrome: Data from the PATRO Children Study — Horm Res Paediatr, 2021](https://pubmed.ncbi.nlm.nih.gov/34350858/)
- [\[Multiple clinical effects of recombinant human growth hormone therapy\] — Zhongguo Dang Dai Er Ke Za Zhi, 2026](https://pubmed.ncbi.nlm.nih.gov/42457321/)
- [Recombinant human growth hormone treatment of Floating-Harbor syndrome: a case report and literature review — BMC Pediatr, 2025](https://pubmed.ncbi.nlm.nih.gov/39905328/)
